Large changes in urinary pH caused by the concurrent use of alkalinising drugs such as
acetazolamide can, in some patients, have a marked effect on the
plasma levels of
mexiletine.
The effect does not appear to be predictable. The manufacturer of
mexiletine recommends that concurrent use should be avoided.